Info Sheet for Technical description

No. 0020

Organization

* Mandatoty fields

Name of Organization*	SanBio Co,Ltd.	
Address, City, States, Zip, Country*	8-1, Akashi-cho, Chuo-ku, Tokyo, 104-0044, Japan	
URL	https://www.sanbio.com/en/	
Brief Descriptions of Organization* (Approx. 100 words)	SanBio focuses on developing products for the central nervous system that are not effectively treated at the present time. Examples of these diseases include dysfunction associated with: stroke, traumatic brain injury, retinal degeneration, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others. Our major pipeline SB623 (allogenic bone marrow-derived mesenchymal stem cells that undergo genetic modification) obtained conditional and time-limited marketing approval in Japan for the treatment of paralysis caused by Traumatic Brain Injury.	
Contact address	Name*	Shinya Hirata
	Department* / Position	Head of Japan Research and Development
	E-mail* / TEL	shinya.hirata@sanbio.com

What kind of technology do you want to offer? *

- ☑ **A.** Clinical Development Pipelines → Please see **Sheet【A】**
- ☐ **B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Servicies etc. → Please see **Sheet【B】**
- ☐ **C.** Platform Technologies(*) that are not included in the above (Group B) → Please see **Sheet【C】**

  * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- ☑ Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

- ☑ Yes
- ☐ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- ☐ Angel / Seed (including AMED/JST grants)
- ☐ Series A
- ☐ Series B
- ☐ Series C
- ☐ Series D or further advenced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
☑ Yes	We can share the brief slide for corporate introduction
☐ No	

Filled in by*	Shinya Hirata
Date*	2025/8/18

Ver.1.0

Sheet【A】 Clinical Development Pipelines

Info Sheet for Technical overview

No. A-0020

* Mandatoty fields

Title*

SB623 (allogenic bone marrow-derived mesenchymal stem cells that undergo genetic modification)

Development Phase*

☐ Basic Research	☐ Drug Discovery	☑ Pre-Clinical
☐ Clinical Trial (Phase I)	☑ Clinical Trial (Phase II)	☑ Clinical Trial (Phase III)
☑ Review	☐ Others	

Diesease Area*

☐ Cancer	☑ Central nervous system	☐ Ophthalmology
☐ Musculoskeletal	☐ Endocrine / Metabolism	☐ Cardiovascular
☐ Urogenital	☐ Digestive organ	☐ Blood
☐ Infection	☐ Dermatology	☐ Immunity
☐ Otolaryngology	☐ Respiratory	☐ Others

Description*

SanBio focuses on developing products for the central nervous system that are not effectively treated at the present time. Examples of these diseases include dysfunction associated with: stroke, traumatic brain injury, retinal degeneration (e.g., age-related macular degeneration), spinal cord injury, Parkinson's disease, Alzheimer's disease, and others.
Our major pipeline SB623 (allogenic bone marrow-derived mesenchymal stem cells that undergo genetic modification) are intended to restore motor and sensory functions by inducing or promoting the innate regenerative processes of patients' brain.
July 2024, SB623 obtained conditional and time-limited marketing approval in Japan for the treatment of paralysis caused by Traumatic Brain Injury.
For the treatment of paralysis caused by chronic stroke, we've already completed P1b study and P2 study in US. We are now plannninng to conduct P3 study in US and initiated the negotiation with FDA.

Filled in by*	Shinya Hirata
Date*	2025/8/18